Viewpoint Molecular Targetin(TM) Commences Patient Enrollment in Phase 1 Imaging Study for VMT01 Program for Metastatic Melanoma ACCESSWIRE 11 Jun 2021, 00:05 GMT+10 - VMT01 Phase 1 imaging study followed by Phase 1/2a therapy study for the treatment of metastatic melanoma being conducted at Mayo Clinic - - Positive preclinical data have demonstrated that a single dose of [212Pb]-VMT01 has significantly arrested melanoma tumor growth and extended survival - - VMT01 imaging study provisional results expected in Q4 2021 - CORALVILLE, IA / ACCESSWIRE / June 10, 2021 / Viewpoint Molecular Targeting, Inc. ('Viewpoint' or the 'Company'), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has initiated patient enrollment and screening in its Phase 1 imaging study evaluating VMT01 for the treatment of metastatic melanoma.